UK markets close in 1 hour 7 minutes
  • FTSE 100

    7,133.37
    +23.40 (+0.33%)
     
  • FTSE 250

    22,605.10
    +94.98 (+0.42%)
     
  • AIM

    1,249.60
    +11.12 (+0.90%)
     
  • GBP/EUR

    1.1637
    -0.0027 (-0.23%)
     
  • GBP/USD

    1.3927
    +0.0006 (+0.04%)
     
  • BTC-GBP

    23,905.68
    -608.85 (-2.48%)
     
  • CMC Crypto 200

    798.49
    -44.16 (-5.24%)
     
  • S&P 500

    4,278.73
    +12.24 (+0.29%)
     
  • DOW

    34,435.61
    +238.79 (+0.70%)
     
  • CRUDE OIL

    73.44
    +0.14 (+0.19%)
     
  • GOLD FUTURES

    1,787.70
    +11.00 (+0.62%)
     
  • NIKKEI 225

    29,066.18
    +190.95 (+0.66%)
     
  • HANG SENG

    29,288.22
    +405.76 (+1.40%)
     
  • DAX

    15,573.25
    -15.98 (-0.10%)
     
  • CAC 40

    6,613.88
    -17.27 (-0.26%)
     

Global Glaucoma Market Pipeline Spotlight Report 2021 - Novartis Leads Industry Sponsors with the Highest Overall Number of Clinical Trials, Followed by AbbVie

·3-min read

Dublin, June 10, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Glaucoma" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Glaucoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, recent events and analyst opinion, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

  • The publisher estimates that in 2019, there were 99.7 million prevalent cases of glaucoma in adults aged 40 years and older worldwide, and forecasts that number to increase to 119.4 million prevalent cases by 2028.

  • Africa is estimated to have the highest disease prevalence (4.79%), while Europe and Oceania have the lowest prevalence (2.93% and 2.97%, respectively).

  • The majority of approved drugs in the glaucoma space target beta adrenergic receptors or the prostaglandin F receptor. Almost all of these approved drugs are administered via the topical route, with the remainder being intraocular/subretinal/subconjunctival or oral formulations.

  • The highest proportion of industry-sponsored drugs in active clinical development for glaucoma are in Phase II, with only one drug in the NDA/BLA phase.

  • While a small number of mid-to-late-stage drugs in the glaucoma space are exploring new targets, the established target prostaglandin F receptor continues to lead clinical development. The largest number of drugs in mid-to-late-stage development for glaucoma are administered via the intraocular/subretinal/subconjunctival route.

  • High-impact upcoming events for drugs in the glaucoma space comprise topline Phase II trial results for GAL-101, topline Phase III trial results for NCX 470, and an expected PDUFA date for DE-117.

  • The overall likelihood of approval of a Phase I glaucoma/ocular hypertension (ophthalmology) asset is 4.9%, and the average probability a drug advances from Phase III is 57.1%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 8.9 years in the overall ophthalmology space.

  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for glaucoma have been in the late phases of development, with 59% of trials in Phase III-IV, and 41% in Phase I-II.

  • The US has a substantial lead in the number of glaucoma clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.

  • Clinical trial activity in the glaucoma space is dominated by completed trials. Novartis has the highest number of completed clinical trials for glaucoma, with 156 trials.

  • Novartis leads industry sponsors with by far the highest overall number of clinical trials for glaucoma, followed by AbbVie

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Eye drops

  • Oral medications

  • Intraocular implants

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • AKB-9778 for Glaucoma (December 11, 2020)

  • Nyxol for Glaucoma (November 7, 2019)

  • NCX 470 for Glaucoma (October 2, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Phesgo & Roclanda Among New Winners at EMA

  • Allergan's Ophthalmic Implant Technology Gets Nod for Durysta

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Upjohn to Divest Three in Australia to Complete on Viatris

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status

  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

Companies Mentioned

  • Allergan

  • Astellas

  • Merck

  • Novartis

  • Q Biomed

  • Santen

For more information about this report visit https://www.researchandmarkets.com/r/jdtmt8

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting